Toward Personalized Medicine: The Effect of Treatment of Chronic Enterovirus Diarrhea in an Immunocompromised Patient and the Correlation With In Vitro Models
Open Access
- 10 April 2025
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (5) , ofaf212
Abstract
Enteroviruses (EV) usually cause acute, mild, self-limiting disease. Chronic infections with EVs are rare, and typically occur in patients with immunodeficiency, posing a high risk of severe outcomes. We report a rare case of chronic diarrhea caused by coxsackievirus A1 (CVA1) (from EV-C species) infection in a patient with a common variable immunodeficiency, who was on treatment with pooled intravenous immunoglobulin (IVIG) from the Netherlands. To explore treatment options, we assessed the presence of neutralizing antibodies (nAbs) against CVA1 in pooled IVIG from South Africa, where EV-Cs are prevalent, and tested the antiviral efficacy of US Food and Drug Administration–approved drugs like fluoxetine, itraconazole, ribavirin, and remdesivir (RDV) against CVA1 in vitro. Both Dutch and South African IVIG showed low nAb titers against CVA1. The patient, treated with Dutch IVIG, also received a combination of amantadine and fluoxetine, which were discontinued due to side effects. Among the drugs tested, only RDV significantly inhibited CVA1 replication in rhabdomyosarcoma (RD) cells. This in vitro efficacy was not reflected by a favorable clinical response after treatment of the patient with RDV. In concordance with unfavorable antiviral response in the patient, preliminary tests on a co-culture model containing isogenic human intestinal cells and intestinal fibroblasts showed no significant reduction in CVA1 RNA copies after RDV administration. In conclusion, our results showed that repurposing of drugs that have shown in vitro efficacy does not translate well to the patients, and this is also reflected in a more physiologically relevant model of the human intestine.Keywords
Funding Information
- European Union’s Horizon 2020 Research and Innovation Programme
- Marie Sklowdowska-Curie Grant Agreement OrganoVIR (812673)
- European Union’s Horizon 2020 Research and Innovation Programme (953201)
- public–private partnership
- Health Holland
This publication has 58 references indexed in Scilit:
- Complete Genome Sequence of Two Coxsackievirus A1 Strains That Were Cytotoxic to Human Rhabdomyosarcoma CellsJournal of Virology, 2012
- Severe Viral Infections and Primary ImmunodeficienciesClinical Infectious Diseases, 2011
- Pleconaril Revisited: Clinical Course of Chronic Enteroviral Meningoencephalitis after Treatment Correlates with In Vitro SusceptibilityAntiviral Therapy, 2011
- Detection of human enterovirus and human parechovirus (HPeV) genotypes from clinical stool samples: polymerase chain reaction and direct molecular typing, culture characteristics, and serotypingDiagnostic Microbiology and Infectious Disease, 2010
- Innate Host Barriers to Viral Trafficking and Population Diversity2010
- Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal nicheNature, 2009
- An Outbreak of Concurrent Echovirus 30 and Coxsackievirus A1 Infections Associated with Sea Swimming among a Group of Travelers to MexicoClinical Infectious Diseases, 2008
- Ribavirin Reduces Mortality in Enterovirus 71–Infected Mice by Decreasing Viral ReplicationThe Journal of Infectious Diseases, 2008
- Protective effect of preexisting rotavirus‐specific immunoglobulin A against naturally acquired rotavirus infection in childrenJournal of Medical Virology, 1987
- OUTBREAK OF COXSACKIE A1 GASTROENTERITIS: A COMPLICATION OF BONE-MARROW TRANSPLANTATIONThe Lancet, 1982